Skip to main content
Top
Published in: Clinical Rheumatology 2/2017

01-02-2017 | Original Article

Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients

Authors: Julia G. Harris, Kristyn I. Maletta, Evelyn M. Kuhn, Judyann C. Olson

Published in: Clinical Rheumatology | Issue 2/2017

Login to get access

Abstract

The aim of this study was to describe compliance with select quality indicators and assess organ-specific dysfunction in a childhood-onset systemic lupus erythematosus population by using a validated damage index and to evaluate associations between compliance with quality indicators and disease damage. A retrospective chart review was performed on patients diagnosed with systemic lupus erythematosus prior to age 18 followed at a single center in the USA from 1999 to 2012 (n = 75). Data regarding quality indicators and outcome variables, including the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, were collected. The median disease duration was 3.8 years. The proportion of patients or patient–years in which care complied with the proposed quality measures was 94.4% for hydroxychloroquine use, 84.3% for vitamin D recommendation,75.8% for influenza vaccination (patient–years), 67.2% for meningococcal vaccination, 49.0% for ophthalmologic examination (patient–years), 31.7% for pneumococcal vaccination, and 28.6% for bone mineral density evaluation. Disease damage was present in 41.3% of patients at last follow-up, with an average damage index score of 0.81. Disease damage at last follow-up was associated with minority race/ethnicity (p = 0.008), bone mineral density evaluation (p = 0.035), and vitamin D recommendation (p = 0.018). Adherence to quality indicators in a childhood-onset systemic lupus erythematosus population is varied, and disease damage is prevalent. This study highlights the importance of quality improvement initiatives aimed at optimizing care delivery to reduce disease damage in pediatric lupus patients.
Literature
1.
go back to reference Yurkovich M, Vostretsova K, Chen W, Aviῆa-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 66:608–616CrossRef Yurkovich M, Vostretsova K, Chen W, Aviῆa-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 66:608–616CrossRef
2.
go back to reference Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444CrossRefPubMed Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444CrossRefPubMed
3.
go back to reference Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE et al (2012) Disease activity, severity, and damage in UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum 64:2356–2365CrossRefPubMed Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE et al (2012) Disease activity, severity, and damage in UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum 64:2356–2365CrossRefPubMed
4.
go back to reference Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velazquez MR et al (2003) Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort. Arthritis Rheum 49:501–507CrossRefPubMed Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velazquez MR et al (2003) Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort. Arthritis Rheum 49:501–507CrossRefPubMed
5.
go back to reference Brunner HI, Gladman DD, Ibaῇez D, Urowitz MD, Silverman ED (2008) Differences in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556–562CrossRefPubMed Brunner HI, Gladman DD, Ibaῇez D, Urowitz MD, Silverman ED (2008) Differences in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556–562CrossRefPubMed
6.
go back to reference Institute of Medicine, Committee on Quality of Health Care in America (2000) To err is human: building a safer health system. National Academy Press, Washington, DC Institute of Medicine, Committee on Quality of Health Care in America (2000) To err is human: building a safer health system. National Academy Press, Washington, DC
7.
go back to reference Institute of Medicine, Committee on Quality of Health Care in America (2001) Crossing the quality chasm: a new health system for the twenty-first century. National Academy Press, Washington, DC Institute of Medicine, Committee on Quality of Health Care in America (2001) Crossing the quality chasm: a new health system for the twenty-first century. National Academy Press, Washington, DC
8.
go back to reference MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH (2004) Measuring quality in arthritis care: methods for developing the Arthritis Foundation’s quality indicator set. Arthritis Rheum 51:193–202CrossRefPubMed MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH (2004) Measuring quality in arthritis care: methods for developing the Arthritis Foundation’s quality indicator set. Arthritis Rheum 51:193–202CrossRefPubMed
9.
go back to reference Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT et al (2004) Quality of care indicators in gout management. Arthritis Rheum 50:937–943CrossRefPubMed Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT et al (2004) Quality of care indicators in gout management. Arthritis Rheum 50:937–943CrossRefPubMed
10.
go back to reference Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M et al (2011) Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 63:10–16CrossRef Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M et al (2011) Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 63:10–16CrossRef
11.
go back to reference Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E (2009) A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 61:370–377CrossRefPubMedPubMedCentral Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E (2009) A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 61:370–377CrossRefPubMedPubMedCentral
12.
go back to reference Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R et al (2011) Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 10:383–388CrossRefPubMedPubMedCentral Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R et al (2011) Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 10:383–388CrossRefPubMedPubMedCentral
13.
go back to reference Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 67:195–205CrossRefPubMed Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 67:195–205CrossRefPubMed
14.
go back to reference Schmajuk G, Yelin E, Chakravarty E, Nelson LM, Panopolis P, Yazdany J (2010) Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care Res (Hoboken) 62:993–1001CrossRef Schmajuk G, Yelin E, Chakravarty E, Nelson LM, Panopolis P, Yazdany J (2010) Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care Res (Hoboken) 62:993–1001CrossRef
15.
go back to reference Demas KL, Keenan BT, Solomon DH, Yazdany J, Costenbader KH (2010) Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators. Semin Arthritis Rheum 40:193–200CrossRefPubMedPubMedCentral Demas KL, Keenan BT, Solomon DH, Yazdany J, Costenbader KH (2010) Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators. Semin Arthritis Rheum 40:193–200CrossRefPubMedPubMedCentral
16.
go back to reference Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH (2014) Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken) 66:617–624CrossRef Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH (2014) Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken) 66:617–624CrossRef
17.
go back to reference Yazdany J, Trupin L, Tonner C, Dudley RA, Zell J, Panopalis P et al (2012) Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care. J Gen Intern Med 27:1326–1333CrossRefPubMedPubMedCentral Yazdany J, Trupin L, Tonner C, Dudley RA, Zell J, Panopalis P et al (2012) Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care. J Gen Intern Med 27:1326–1333CrossRefPubMedPubMedCentral
18.
go back to reference Hollander MC, Sage JM, Greenler AJ, Pendl J, Avcin T, Espada G et al (2013) International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65:1416–1423CrossRef Hollander MC, Sage JM, Greenler AJ, Pendl J, Avcin T, Espada G et al (2013) International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65:1416–1423CrossRef
19.
go back to reference Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRefPubMed Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRefPubMed
20.
go back to reference Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R et al (2006) A proposal for a pediatric version of the systemic lupus international collaborating clinics/American College of Rheumatology damage index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 54:2989–2996CrossRefPubMed Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R et al (2006) A proposal for a pediatric version of the systemic lupus international collaborating clinics/American College of Rheumatology damage index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 54:2989–2996CrossRefPubMed
21.
go back to reference Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A et al (2006) Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 15:515–520CrossRefPubMed Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A et al (2006) Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 15:515–520CrossRefPubMed
22.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed
23.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed
24.
go back to reference Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. (2004)The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int65:521–530. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. (2004)The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int65:521–530.
26.
go back to reference Barlow SE, the Expert Committee (2007) Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120(4):164–192CrossRef Barlow SE, the Expert Committee (2007) Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120(4):164–192CrossRef
27.
go back to reference Centers for Disease Control and Prevention (2010) Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine— recommendations of the advisory committee on immunization practices (ACIP). MMWR 59:1–18 Centers for Disease Control and Prevention (2010) Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine— recommendations of the advisory committee on immunization practices (ACIP). MMWR 59:1–18
28.
go back to reference Centers for Disease Control and Prevention (2012) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR 61:816–819 Centers for Disease Control and Prevention (2012) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR 61:816–819
29.
go back to reference Centers for Disease Control and Prevention (2005) Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practice (ACIP). MMWR 54:1–21 Centers for Disease Control and Prevention (2005) Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practice (ACIP). MMWR 54:1–21
30.
go back to reference Centers for Disease Control and Prevention (2011) Updated recommendations for use of meningococcal conjugate vaccines: advisory committee on immunization practice (ACIP), 2010. MMWR 60:72–76 Centers for Disease Control and Prevention (2011) Updated recommendations for use of meningococcal conjugate vaccines: advisory committee on immunization practice (ACIP), 2010. MMWR 60:72–76
32.
go back to reference Lacks S, White P (1990) Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol 17:941–945PubMed Lacks S, White P (1990) Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol 17:941–945PubMed
33.
go back to reference Bachrach LK, Sills LN (2011) Clinical report—bone densitometry in children and adolescents. Pediatrics 127:189–194CrossRefPubMed Bachrach LK, Sills LN (2011) Clinical report—bone densitometry in children and adolescents. Pediatrics 127:189–194CrossRefPubMed
34.
go back to reference Mina R, Harris JG, Klein-Gitelman MS, Appenzeller S, Centeville M, Eskra D et al (2016) Initial benchmarking of the quality of medical care of childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 68:179–186CrossRef Mina R, Harris JG, Klein-Gitelman MS, Appenzeller S, Centeville M, Eskra D et al (2016) Initial benchmarking of the quality of medical care of childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 68:179–186CrossRef
35.
go back to reference Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L et al (2009) Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 61:13–20CrossRefPubMedPubMedCentral Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L et al (2009) Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 61:13–20CrossRefPubMedPubMedCentral
36.
go back to reference Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515–1526CrossRef Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515–1526CrossRef
37.
go back to reference Lim LS, Benseler SM, Tyrrell PN, Harvey E, Herbert D, Charron M, Silverman ED (2012) Predicting longitudinal trajectory of bone mineral density in paediatric systemic lupus erythematosus patients. Ann Rheum Dis 71:1686–1691CrossRefPubMed Lim LS, Benseler SM, Tyrrell PN, Harvey E, Herbert D, Charron M, Silverman ED (2012) Predicting longitudinal trajectory of bone mineral density in paediatric systemic lupus erythematosus patients. Ann Rheum Dis 71:1686–1691CrossRefPubMed
38.
go back to reference Casella CB, Seguro LPC, Takayama L, Medeiros D, Bonfa E, Pereira RMR (2012) Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health. Lupus 21:1335–1342CrossRefPubMed Casella CB, Seguro LPC, Takayama L, Medeiros D, Bonfa E, Pereira RMR (2012) Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health. Lupus 21:1335–1342CrossRefPubMed
39.
go back to reference Caetano M, Terreri MT, Ortiz T, Pinheiro M, Souza F, Sarni R (2015) Bone mineral density reduction in adolescents with systemic erythematosus lupus: association with lack of vitamin D supplementation. Clin Rheumatol 34:2065–2070CrossRefPubMed Caetano M, Terreri MT, Ortiz T, Pinheiro M, Souza F, Sarni R (2015) Bone mineral density reduction in adolescents with systemic erythematosus lupus: association with lack of vitamin D supplementation. Clin Rheumatol 34:2065–2070CrossRefPubMed
40.
go back to reference Yazdany J, Tonner C, Trupin L, Panopalis P, Gillis JZ, Hersh AO et al (2010) Provision of preventative health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Res Ther 12:r84CrossRefPubMedPubMedCentral Yazdany J, Tonner C, Trupin L, Panopalis P, Gillis JZ, Hersh AO et al (2010) Provision of preventative health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Res Ther 12:r84CrossRefPubMedPubMedCentral
41.
go back to reference Annunziata K, Rak A, Del Buono H, DiBonaventura M, Krishnarajah G (2012) Vaccination rates among the general adult population and high-risk groups in the United States. PLoS One 7:e50553CrossRefPubMedPubMedCentral Annunziata K, Rak A, Del Buono H, DiBonaventura M, Krishnarajah G (2012) Vaccination rates among the general adult population and high-risk groups in the United States. PLoS One 7:e50553CrossRefPubMedPubMedCentral
43.
go back to reference Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:309–318CrossRefPubMed Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:309–318CrossRefPubMed
44.
go back to reference Sutcliffe N, Clarke AE, Gordon C, Farewell V, Isenberg DA (1999) The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) 38:1130–1137CrossRef Sutcliffe N, Clarke AE, Gordon C, Farewell V, Isenberg DA (1999) The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) 38:1130–1137CrossRef
Metadata
Title
Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients
Authors
Julia G. Harris
Kristyn I. Maletta
Evelyn M. Kuhn
Judyann C. Olson
Publication date
01-02-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 2/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3518-0

Other articles of this Issue 2/2017

Clinical Rheumatology 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.